Close Menu

NEW YORK (GenomeWeb News) – BG Medicine has been warned by Nasdaq that it fails to meet a requirement to remain listed on the Nasdaq Capital Market, the company said in a document filed last week with the US Securities and Exchange Commission.

In a November 20 letter from Nasdaq, BG Medicine was told that it did not meet the minimum $2.5 million in stockholders' equity required for listing on the exchange, putting the company at risk of being delisted. For the period ended Sept. 30, 2014, BG Medicine reported stockholders' equity of $1.7 million.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

A German shepherd called Nala has had her genome sequenced.

A coronavirus serology test garners Emergency Use Authorization from the US Food and Drug Administration, but the Los Angeles Times asks: how will tests like that be used?

Certain gene variants in conjunction with a healthy lifestyle may keep brains young, according to New Scientist.

In Science this week: increased CD8 T cell density and increased IFN-gamma response may indicate metastatic prostate cancer patients who will respond to immune checkpoint blockade therapy.

Apr
09
Sponsored by
GenomeWeb/ABRF

This webinar will discuss SCoPE2 (Single Cell Proteomics by Mass Spectrometry, Version 2), an approach for quantitatively analyzing proteins in single cells using only commercially available equipment and reagents.

Apr
16
Sponsored by
GenomeWeb/ABRF

This webinar will discuss a mass spectrometry-based metaproteomic approach to examine microbiome temporal functional shifts during microbial colonization of the preterm human infant gut.